(Total Views: 658)
Posted On: 12/07/2023 5:22:38 PM
Post# of 148870
We will see next Thursday. I will just offer this comment: In the interim Gilead can flush all the ant-retrovirals they want down people’s throats but this next study is a not a chess draw, it is check-mate.
If Leronlimab shows both viral suppression (we already checked that box) AND immune modulation, without which patients subject themselves to related co-morbidities and premature mortality…with virtually no side effects…it would likely SUPPLANT existing multi-drug regimens with side effects sufficient to open the door to patient compliance issues and by extension drug resistance…and become STANDARD OF CARE. Monotherapy with a superior drug means you own the market.
Checkmate. Gilead might be forced to write a very big check to secure their franchise which will otherwise wither.
I stand by my comment, this protocol has to be bulletproof, it is of critical importance to Cytodyn’s future.
If Leronlimab shows both viral suppression (we already checked that box) AND immune modulation, without which patients subject themselves to related co-morbidities and premature mortality…with virtually no side effects…it would likely SUPPLANT existing multi-drug regimens with side effects sufficient to open the door to patient compliance issues and by extension drug resistance…and become STANDARD OF CARE. Monotherapy with a superior drug means you own the market.
Checkmate. Gilead might be forced to write a very big check to secure their franchise which will otherwise wither.
I stand by my comment, this protocol has to be bulletproof, it is of critical importance to Cytodyn’s future.
(8)
(0)Scroll down for more posts ▼
